EPISODE · Sep 18, 2025 · 1 MIN
ACT Brief: Policy Shifts, FDA Inspections, and Tariffs Pose New Challenges for Clinical Trials
from Applied Clinical Trials · host Applied Clinical Trials
In this episode of the ACT Brief, we spotlight an earlier interview with Ron Lanton, partner at Lanton Law, in which he discussed how rising drug costs, reduced FDA inspections, and potential tariffs on active pharmaceutical ingredients could increase costs and slow progress across the clinical research landscape.
Embed this episode
Ready to play
ACT Brief: Policy Shifts, FDA Inspections, and Tariffs Pose New Challenges for Clinical Trials
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.